Skip to main content

Sarepta Drops After U.K. Trial Halt, But Analysts Unconcerned

Shares of Sarepta Therapeutics dropped in morning trading following a report that said that the company had halted treatment at sites in the United Kingdom testing its Duchenne muscular dystrophy drug golodirsen.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.